Main distributor to Brazil and Latin America for analytical reference substances  |  Welcome! Olá! Hola! Español  |  +1.919.484.7555
You are here: Home /News

News

New way to test for drug resistant infections: Scientists have developed a method to test whether an infection is resistant to common antibiotics — ScienceDaily

Scientists have developed a method to test whether an infection is resistant to common antibiotics. Beta-lactam antibiotics (such as penicillin) are one of the most important classes of antibiotics, but resistance to them has grown to such an extent that doctors often avoid prescribing them in favour of stronger drugs. Scientists from the University of […]

Posted in Research, Science, Technology | Leave a comment

Deadly ‘superbugs’ destroyed by molecular drills — ScienceDaily

Molecular drills have gained the ability to target and destroy deadly bacteria that have evolved resistance to nearly all antibiotics. In some cases, the drills make the antibiotics effective once again. Researchers at Rice University, Texas A&M University, Biola University and Durham (U.K.) University showed that motorized molecules developed in the Rice lab of chemist […]

Posted in Research, Science | Leave a comment

Japan approves ViiV’s two drug regimen Dovato for HIV

ViiV Healthcare’s human immunodeficiency virus (HIV) drug Dovato (dolutegravir 50mg/lamivudine 300mg) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW). Dovato is a once-daily, single pill, two-drug regimen approved to treat adults and adolescents aged over 12 with HIV type 1 (HIV-1) infection who weigh more than 40kg. The drug is […]

Posted in Drug, Science | Leave a comment

Novo Nordisk secures FDA expanded indication for Ozempic

The US Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk’s Ozempic (semaglutide). The once-weekly injection is now indicated to reduce the risk of major adverse cardiovascular events (MACE), such as non-fatal heart attack or stroke and cardiovascular death, in adults with type 2 diabetes and established cardiovascular disease (CVD). FDA […]

Posted in FDA | Leave a comment

FDA grants Clovis’ Rubraca fast track designation for prostate cancer

By Allie Nawrat Colorado-based Clovis Oncology has received fast track designation from the US Food and Drug Administration (FDA) for Rubraca (rucaparib) as a monotherapy for BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer (mCRPC) adult patients. Rubraca is an oral, small molecule inhibitor of poly ADP-ribose polymerase (PARP) 1, 2 and 3, being developed in multiple solid […]

Posted in Cancer | Leave a comment

Mitochondria are the ‘canary in the coal mine’ for cellular stress: How some cancers resist chemotherapy — ScienceDaily

Mitochondria, tiny structures present in most cells, are known for their energy-generating machinery. Now, Salk researchers have discovered a new function of mitochondria: they set off molecular alarms when cells are exposed to stress or chemicals that can damage DNA, such as chemotherapy. The results, published online in Nature Metabolism on December 9, 2019, could lead to […]

Posted in Cancer | Comments Off on Mitochondria are the ‘canary in the coal mine’ for cellular stress: How some cancers resist chemotherapy — ScienceDaily

Deadly ‘superbugs’ destroyed by molecular drills — ScienceDaily

Molecular drills have gained the ability to target and destroy deadly bacteria that have evolved resistance to nearly all antibiotics. In some cases, the drills make the antibiotics effective once again. Researchers at Rice University, Texas A&M University, Biola University and Durham (U.K.) University showed that motorized molecules developed in the Rice lab of chemist […]

Posted in Science | Comments Off on Deadly ‘superbugs’ destroyed by molecular drills — ScienceDaily

Cancer trials bias: can patients trust the trial data for novel therapies?

With cancer cases on the rise globally, partly driven by the world’s growing and ageing population, it’s understandable that drug regulators are keen to speed up approvals of novel cancer therapies through mechanisms like accelerated approval pathways, which are being granted to drug development programmes with increasing frequency. But, does the need for speed come […]

Posted in Cancer | Comments Off on Cancer trials bias: can patients trust the trial data for novel therapies?

GBT and Syros team up on new therapies for blood disorders

Global Blood Therapeutics (GBT) has signed an agreement with Syros Pharmaceuticals for the discovery, development and commercialisation of therapies to treat two blood disorders. As part of the partnership, Syros will leverage its gene control platform to identify therapeutic targets for sickle cell disease (SCD) and beta thalassemia. The aim is to discover drugs that […]

Posted in Science, Technology | Comments Off on GBT and Syros team up on new therapies for blood disorders

Syncona invests $80m in Freeline’s systemic disease gene therapies

By Allie Nawrat Syncona has committed to investing $80m in gene therapy-focused Freeline’s Series C financing round. This builds upon Syncona’s status as the biotech’s founding investor and its previous total £123.2m ($161.5m) investment in Freeline’s Series A and B funding rounds. Freeline is planning to use the $40m already received from Syncona to further strengthen […]

Posted in Research, Science | Comments Off on Syncona invests $80m in Freeline’s systemic disease gene therapies